Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
Executive Summary
While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.